vs

Side-by-side financial comparison of Becton Dickinson (BDX) and Macy's, Inc. (M). Click either name above to swap in a different company.

Becton Dickinson is the larger business by last-quarter revenue ($5.3B vs $4.7B, roughly 1.1× Macy's, Inc.). Becton Dickinson runs the higher net margin — 7.3% vs 0.2%, a 7.0% gap on every dollar of revenue. On growth, Becton Dickinson posted the faster year-over-year revenue change (-0.4% vs -0.6%). Becton Dickinson produced more free cash flow last quarter ($549.0M vs $-101.0M). Over the past eight quarters, Becton Dickinson's revenue compounded faster (2.0% CAGR vs -23.8%).

Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.

Macy's, Inc. is an American holding company of department stores. Upon its establishment in 1929, Federated held ownership of the regional department store chains Abraham & Straus, Lazarus, Filene's, and Shillito's. Bloomingdale's joined Federated Department Stores the next year. Throughout its early history, frequent acquisitions and divestitures saw the company operate a number of nameplates. In 1994, Federated took over Macy's, the old department store chain originally founded in 1858 by A...

BDX vs M — Head-to-Head

Bigger by revenue
BDX
BDX
1.1× larger
BDX
$5.3B
$4.7B
M
Growing faster (revenue YoY)
BDX
BDX
+0.2% gap
BDX
-0.4%
-0.6%
M
Higher net margin
BDX
BDX
7.0% more per $
BDX
7.3%
0.2%
M
More free cash flow
BDX
BDX
$650.0M more FCF
BDX
$549.0M
$-101.0M
M
Faster 2-yr revenue CAGR
BDX
BDX
Annualised
BDX
2.0%
-23.8%
M

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
BDX
BDX
M
M
Revenue
$5.3B
$4.7B
Net Profit
$382.0M
$11.0M
Gross Margin
45.9%
39.4%
Operating Margin
10.5%
0.9%
Net Margin
7.3%
0.2%
Revenue YoY
-0.4%
-0.6%
Net Profit YoY
24.0%
-60.7%
EPS (diluted)
$1.34
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDX
BDX
M
M
Q4 25
$5.3B
$4.7B
Q3 25
$5.9B
$4.8B
Q2 25
$5.5B
$4.6B
Q1 25
$5.3B
$7.8B
Q4 24
$5.2B
$4.7B
Q3 24
$5.4B
$4.9B
Q2 24
$5.0B
$4.8B
Q1 24
$5.0B
$8.1B
Net Profit
BDX
BDX
M
M
Q4 25
$382.0M
$11.0M
Q3 25
$493.0M
$87.0M
Q2 25
$574.0M
$38.0M
Q1 25
$308.0M
$342.0M
Q4 24
$303.0M
$28.0M
Q3 24
$400.0M
$150.0M
Q2 24
$487.0M
$62.0M
Q1 24
$537.0M
$-71.0M
Gross Margin
BDX
BDX
M
M
Q4 25
45.9%
39.4%
Q3 25
47.5%
39.7%
Q2 25
47.8%
39.2%
Q1 25
42.8%
35.7%
Q4 24
43.2%
39.6%
Q3 24
45.7%
40.5%
Q2 24
46.2%
39.2%
Q1 24
45.7%
37.5%
Operating Margin
BDX
BDX
M
M
Q4 25
10.5%
0.9%
Q3 25
11.8%
3.1%
Q2 25
16.0%
2.0%
Q1 25
10.4%
6.4%
Q4 24
8.8%
1.3%
Q3 24
11.4%
4.5%
Q2 24
12.1%
2.6%
Q1 24
14.5%
-0.9%
Net Margin
BDX
BDX
M
M
Q4 25
7.3%
0.2%
Q3 25
8.4%
1.8%
Q2 25
10.4%
0.8%
Q1 25
5.8%
4.4%
Q4 24
5.9%
0.6%
Q3 24
7.4%
3.0%
Q2 24
9.8%
1.3%
Q1 24
10.6%
-0.9%
EPS (diluted)
BDX
BDX
M
M
Q4 25
$1.34
$0.04
Q3 25
$1.71
$0.31
Q2 25
$2.00
$0.13
Q1 25
$1.07
$1.22
Q4 24
$1.04
$0.10
Q3 24
$1.37
$0.53
Q2 24
$1.68
$0.22
Q1 24
$1.85
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDX
BDX
M
M
Cash + ST InvestmentsLiquidity on hand
$740.0M
$447.0M
Total DebtLower is stronger
$2.4B
Stockholders' EquityBook value
$25.3B
$4.3B
Total Assets
$54.8B
$17.1B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDX
BDX
M
M
Q4 25
$740.0M
$447.0M
Q3 25
$641.0M
$829.0M
Q2 25
$735.0M
$932.0M
Q1 25
$667.0M
$1.3B
Q4 24
$711.0M
$315.0M
Q3 24
$1.7B
$646.0M
Q2 24
$4.5B
$876.0M
Q1 24
$2.3B
$1.0B
Total Debt
BDX
BDX
M
M
Q4 25
$2.4B
Q3 25
$2.4B
Q2 25
$2.8B
Q1 25
$2.8B
Q4 24
$2.8B
Q3 24
$3.0B
Q2 24
$3.0B
Q1 24
$3.0B
Stockholders' Equity
BDX
BDX
M
M
Q4 25
$25.3B
$4.3B
Q3 25
$25.4B
$4.5B
Q2 25
$25.5B
$4.5B
Q1 25
$25.2B
$4.6B
Q4 24
$25.2B
$4.1B
Q3 24
$25.9B
$4.3B
Q2 24
$25.9B
$4.2B
Q1 24
$25.6B
$4.1B
Total Assets
BDX
BDX
M
M
Q4 25
$54.8B
$17.1B
Q3 25
$55.3B
$15.6B
Q2 25
$54.9B
$16.1B
Q1 25
$54.5B
$16.4B
Q4 24
$54.7B
$17.3B
Q3 24
$57.3B
$15.8B
Q2 24
$55.6B
$16.4B
Q1 24
$54.2B
$16.2B
Debt / Equity
BDX
BDX
M
M
Q4 25
0.56×
Q3 25
0.55×
Q2 25
0.62×
Q1 25
0.61×
Q4 24
0.67×
Q3 24
0.70×
Q2 24
0.72×
Q1 24
0.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDX
BDX
M
M
Operating Cash FlowLast quarter
$657.0M
$-8.0M
Free Cash FlowOCF − Capex
$549.0M
$-101.0M
FCF MarginFCF / Revenue
10.5%
-2.1%
Capex IntensityCapex / Revenue
2.1%
2.0%
Cash ConversionOCF / Net Profit
1.72×
-0.73×
TTM Free Cash FlowTrailing 4 quarters
$2.6B
$1.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDX
BDX
M
M
Q4 25
$657.0M
$-8.0M
Q3 25
$1.4B
$319.0M
Q2 25
$1.2B
$-64.0M
Q1 25
$164.0M
$1.3B
Q4 24
$693.0M
$-167.0M
Q3 24
$1.2B
$8.0M
Q2 24
$1.3B
$129.0M
Q1 24
$514.0M
$1.1B
Free Cash Flow
BDX
BDX
M
M
Q4 25
$549.0M
$-101.0M
Q3 25
$1.0B
$240.0M
Q2 25
$1.0B
$-164.0M
Q1 25
$35.0M
$1.2B
Q4 24
$588.0M
$-295.0M
Q3 24
$882.0M
$-109.0M
Q2 24
$1.1B
$-25.0M
Q1 24
$380.0M
$1.0B
FCF Margin
BDX
BDX
M
M
Q4 25
10.5%
-2.1%
Q3 25
17.0%
5.0%
Q2 25
19.0%
-3.6%
Q1 25
0.7%
15.3%
Q4 24
11.4%
-6.2%
Q3 24
16.2%
-2.2%
Q2 24
22.4%
-0.5%
Q1 24
7.5%
12.3%
Capex Intensity
BDX
BDX
M
M
Q4 25
2.1%
2.0%
Q3 25
6.0%
1.6%
Q2 25
3.2%
2.2%
Q1 25
2.4%
1.5%
Q4 24
2.0%
2.7%
Q3 24
5.4%
2.4%
Q2 24
3.6%
3.2%
Q1 24
2.7%
1.8%
Cash Conversion
BDX
BDX
M
M
Q4 25
1.72×
-0.73×
Q3 25
2.75×
3.67×
Q2 25
2.12×
-1.68×
Q1 25
0.53×
3.82×
Q4 24
2.29×
-5.96×
Q3 24
2.94×
0.05×
Q2 24
2.66×
2.08×
Q1 24
0.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BDX
BDX

Other$2.8B53%
Medication Management Solutions$678.0M13%
Urologyand Critical Care$339.0M6%
Surgery$310.0M6%
Peripheral Intervention$265.0M5%
Specimen Management$245.0M5%
Advanced Patient Monitoring$178.0M3%
Diagnostic Solutions$176.0M3%
Bio Pharma Systems$150.0M3%
Biosciences$124.0M2%

M
M

Womens Accessories Shoes Cosmetics And Fragrances$1.9B41%
Womens Apparel$1.1B23%
Mens And Kids$1.0B22%
Home Other$638.0M14%
Credit Card Revenues Net$158.0M3%
Macys Media Network Revenue Net$42.0M1%

Related Comparisons